Daniel Haymann specializes in corporate and commercial law. Based on his extensive business experience, he has a good feel for new markets and understands the requirements of go-to-market and scale-up strategies. As an interdisciplinary and hands-on advisor, his focus is on investments, venture capital and financing transactions as well as regulatory issues in the healthcare and consumer goods sectors.

He advises investors, start-ups and vertically integrated companies along the value chain, including on regulatory issues relating to THC, CBD and other cannabinoids and psychoactive substances, GMP and GDP standards, food and cosmetics regulations and approval procedures before Swissmedic, the Swiss remedy institute.

Daniel is co-founder and co-chair of the European branch of the International Cannabis Bar Association (INCBA Europe). As a Swiss-Israeli dual citizen, he also focuses on serving clients with connections to Israel and strengthening the relevant business relationships.

Prior to his career as a lawyer, Daniel spent over 10 years in senior positions as a commodity trader for multinational corporations.